LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

Home・Akcijų sąrašas・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Uždarymo kaina

1.3 0.78

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.27

Max

1.32

Pagrindiniai rodikliai
By Trading Economics
Pajamos	2.7M -24M
Pelnas, tenkantis vienai akcijai	-0.354
Darbuotojai	171
EBITDA	-5.3M -28M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+108.59% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-615K 80M
Ankstesnė atidarymo kaina	0.52
Ankstesnė uždarymo kaina	1.3

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

1.43 / 1.6 Palaikymas ir pasipriešinimas

Pliant Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-18 22:51; UTC

Uždarbis

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

2026-03-18 21:40; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

2026-03-18 20:31; UTC

Uždarbis

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

2026-03-18 23:49; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

2026-03-18 23:31; UTC

Rinkos pokalbiai

Gold Rises on Likely Technical Recovery -- Market Talk

2026-03-18 22:49; UTC

Rinkos pokalbiai

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

2026-03-18 22:41; UTC

Rinkos pokalbiai

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

2026-03-18 22:36; UTC

Uždarbis

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

2026-03-18 22:24; UTC

Uždarbis

AIA Group Announces New Share Buyback of $1.7B >1299.HK

2026-03-18 22:23; UTC

Uždarbis

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

2026-03-18 22:23; UTC

Uždarbis

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

2026-03-18 21:58; UTC

Uždarbis

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

2026-03-18 21:55; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-03-18 21:55; UTC

Rinkos pokalbiai

Uždarbis

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

2026-03-18 21:40; UTC

Rinkos pokalbiai

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

2026-03-18 21:16; UTC

Rinkos pokalbiai

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

2026-03-18 21:00; UTC

Svarbiausios naujienos

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

2026-03-18 20:58; UTC

Uždarbis

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

2026-03-18 20:41; UTC

Uždarbis

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026-03-18 20:29; UTC

Uždarbis

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026-03-18 20:25; UTC

Uždarbis

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026-03-18 20:17; UTC

Uždarbis

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

2026-03-18 20:14; UTC

Rinkos pokalbiai

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

2026-03-18 20:09; UTC

Uždarbis

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

2026-03-18 20:07; UTC

Uždarbis

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

2026-03-18 20:06; UTC

Uždarbis

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

2026-03-18 20:04; UTC

Uždarbis

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

2026-03-18 20:04; UTC

Uždarbis

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

2026-03-18 20:04; UTC

Uždarbis

Micron Technology Sees 3Q Gross Margin About 81% >MU

2026-03-18 20:03; UTC

Uždarbis

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Akcijų palyginimas

Kainos pokytis

Pliant Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

108.59% į viršų

12 mėnesių prognozė

Vidutinis 2.67 USD 108.59%

Aukščiausias 3 USD

Žemiausias 2 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pliant Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Pliant Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.43 / 1.6Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

There is one bearish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.